Affinity Asset Advisors LLC Sells 354,751 Shares of Context Therapeutics Inc. $CNTX

Key Points

• Affinity Asset Advisors LLC has reduced its stake in Context Therapeutics Inc. by 34.9%, now holding 660,589 shares valued at $404,000.
• Context Therapeutics' stock price has decreased by 2.3%, currently trading at $0.8729, with a market capitalization of $78.30 million.
• Insider trading activity included CFO Jennifer Lynn Minai-Azary purchasing 40,010 shares and CEO Martin A. Lehr buying 100,000 shares, both indicating increased confidence in the company's prospects.

Affinity Asset Advisors LLC reduced its stake in shares of Context Therapeutics Inc. (NASDAQ:CNTX - Free Report) by 34.9% during the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 660,589 shares of the company's stock after selling 354,751 shares during the period. Affinity Asset Advisors LLC owned approximately 0.74% of Context Therapeutics worth $404,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently bought and sold shares of the stock. Jane Street Group LLC acquired a new stake in Context Therapeutics during the 4th quarter worth approximately $29,000. Citadel Advisors LLC acquired a new stake in shares of Context Therapeutics in the fourth quarter valued at approximately $31,000. Millennium Management LLC raised its holdings in shares of Context Therapeutics by 24.2% in the fourth quarter. Millennium Management LLC now owns 178,718 shares of the company's stock valued at $188,000 after purchasing an additional 34,835 shares during the last quarter. Shay Capital LLC acquired a new stake in shares of Context Therapeutics in the fourth quarter valued at approximately $52,000. Finally, Geode Capital Management LLC raised its holdings in shares of Context Therapeutics by 9.2% in the fourth quarter. Geode Capital Management LLC now owns 628,729 shares of the company's stock valued at $661,000 after purchasing an additional 52,830 shares during the last quarter. 14.03% of the stock is currently owned by institutional investors and hedge funds.

Context Therapeutics Stock Down 1.4%

Shares of NASDAQ:CNTX traded down $0.01 during midday trading on Friday, hitting $0.84. The stock had a trading volume of 82,615 shares, compared to its average volume of 172,341. Context Therapeutics Inc. has a 12 month low of $0.49 and a 12 month high of $2.59. The business's 50-day simple moving average is $0.75 and its 200-day simple moving average is $0.75. The company has a market cap of $75.35 million, a P/E ratio of -2.33 and a beta of 1.89.

Context Therapeutics (NASDAQ:CNTX - Get Free Report) last released its earnings results on Wednesday, August 6th. The company reported ($0.09) earnings per share for the quarter, missing the consensus estimate of ($0.06) by ($0.03). As a group, equities analysts predict that Context Therapeutics Inc. will post -0.51 earnings per share for the current year.

Insiders Place Their Bets

In related news, CEO Martin A. Lehr acquired 100,000 shares of Context Therapeutics stock in a transaction on Monday, June 9th. The stock was purchased at an average cost of $0.70 per share, with a total value of $70,000.00. Following the completion of the transaction, the chief executive officer directly owned 920,190 shares in the company, valued at $644,133. This trade represents a 12.19% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Jennifer Lynn Minai-Azary acquired 40,010 shares of Context Therapeutics stock in a transaction on Friday, June 6th. The shares were bought at an average cost of $0.64 per share, with a total value of $25,606.40. Following the completion of the transaction, the chief financial officer owned 80,010 shares of the company's stock, valued at approximately $51,206.40. This trade represents a 100.03% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last ninety days, insiders have acquired 160,010 shares of company stock valued at $107,206. Company insiders own 2.80% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on CNTX. Piper Sandler reiterated an "overweight" rating and issued a $4.00 price objective (down from $4.50) on shares of Context Therapeutics in a report on Thursday, June 26th. HC Wainwright lowered their price objective on shares of Context Therapeutics from $5.00 to $4.00 and set a "buy" rating on the stock in a report on Thursday, August 7th. Finally, D. Boral Capital reiterated a "buy" rating and issued a $9.00 price objective on shares of Context Therapeutics in a report on Thursday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating and five have given a Buy rating to the company's stock. According to MarketBeat, the company has an average rating of "Buy" and a consensus price target of $5.25.

Context Therapeutics Company Profile

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.